Cardiac Imaging Before Cardioversion for Atrial Fibrillation
(LACLOT Trial)
Trial Summary
What is the purpose of this trial?
Evaluating contrast enhanced ECG-gated cardiac CT (CCT) as an alternative to transesophageal echocardiography (TEE) to expedite cardioversion of atrial fibrillation (AF), improve patient care and reduce hospital admissions for AF and atrial flutter.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Cardiac Imaging Before Cardioversion for Atrial Fibrillation?
Research shows that cardiac computed tomography angiography (CCTA) is useful in evaluating heart conditions, such as congenital heart disease, and in guiding treatment after heart procedures. This suggests that CCTA can provide valuable information for managing atrial fibrillation, especially when other imaging methods are unclear.12345
Is cardiac imaging before cardioversion for atrial fibrillation safe?
How does the treatment of cardiac imaging before cardioversion for atrial fibrillation differ from other treatments?
This treatment uses advanced imaging techniques like Contrast Enhanced Cardiac CT (CCT) and Transesophageal Echocardiography (TEE) to safely guide cardioversion by screening for blood clots in the heart, potentially allowing for earlier and safer cardioversion compared to traditional methods that rely on prolonged anticoagulation therapy.111121314
Research Team
Benjamin Chow, MD
Principal Investigator
UOHI
Eligibility Criteria
This trial is for adults over 18 who need imaging of the left atrium before cardioversion, a procedure to correct heart rhythm. Participants must be able to hold their breath for 20 seconds and follow study procedures. It's not for pregnant individuals, those with severe kidney issues (GFR<45ml/min), or certain medical conditions like esophageal problems, unstable heart conditions, or allergies to contrast agents.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Contrast enhanced ECG-gated cardiac CT (CCT)
- Transesophageal Echocardiography (TEE)
Contrast enhanced ECG-gated cardiac CT (CCT) is already approved in European Union, United States, Canada for the following indications:
- Coronary artery disease diagnosis
- Cardiac structural anomalies
- Thoracic vascular congenital and acquired diseases
- Preoperative assessment for noncoronary cardiac surgery
- Evaluation of coronary artery bypass grafts
- Intermediate pretest probability for coronary artery disease
- Unexplained or atypical chest pain
- Preoperative assessment for transcatheter aortic valve implantation (TAVI/TAVR)
- Evaluation of coronary artery stents >3 mm
- New onset heart failure
- Noninvasive evaluation of coronary artery anomalies and other thoracic vessels
- Symptomatic patients with low/moderate probability of coronary artery disease
- Normal or uninterpretable/non-diagnostic ECG
- Normal or equivocal cardiac biomarkers
Find a Clinic Near You
Who Is Running the Clinical Trial?
Ottawa Heart Institute Research Corporation
Lead Sponsor